<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02889744</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH0620160330</org_study_id>
    <nct_id>NCT02889744</nct_id>
  </id_info>
  <brief_title>Comparison of Cerebral SctO2 Between 36℃ and 33℃ of TTM After Cardiac Arrest</brief_title>
  <official_title>Comparison of Cerebral Tissue Oxygen Saturation (SctO2) Between 36℃ and 33℃ of Targeted Temperature Management (TTM) After Cardiac Arrest</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bard Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that&#xD;
&#xD;
        1. if decrease in SctO2 level is caused by the degree of hypothermia, SctO2 level in the&#xD;
           33-TH may be lower than that in the 36-TH group.&#xD;
&#xD;
        2. if decrease in SctO2 level is not caused by the degree of hypothermia but caused by&#xD;
           brain injury, SctO2 level may be associated with only the prognosis of cardiac arrest&#xD;
           victims regardless of core temperatures.&#xD;
&#xD;
      The primary objective of this study is to compare the 72-hour changes in SctO2 level between&#xD;
      the 36-TH and 33-TH groups in cardiac arrest victims.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Subject Identification and Screening For each cohort, patients will be identified after&#xD;
           acquisition of sustained return of spontaneous circulation (ROSC) (&gt; 30 minutes). If the&#xD;
           patients meet inclusion/exclusion criteria, patients will be enrolled in the study. The&#xD;
           investigators will obtain written informed consent from all of the patients or their&#xD;
           representatives.&#xD;
&#xD;
        2. Assignment of Subject Number A unique identification number will be given to study&#xD;
           subjects in an attempt to de-identify their information. Subject numbers will be&#xD;
           assigned in sequential order. The subject number will consist of four digits. The first&#xD;
           two digits will designate the study site. The last two digits will designate the subject&#xD;
           by number in sequential order (i.e., subject number 01 01 will be the first subject at&#xD;
           site 1; 01 02 will be the second subject at site 1, etc.).&#xD;
&#xD;
        3. Study Methods&#xD;
&#xD;
             -  Randomization to 36-TH (core body temperature (BT) 36℃) or 33-TH (core BT 33℃)&#xD;
                group will be performed by a web based randomization site (http://mrcc.snuh.org).&#xD;
&#xD;
             -  Start target temperature management using external cooling device (Arctic Sun)&#xD;
                within 1 hour post-ROSC.&#xD;
&#xD;
             -  SctO2 monitoring starts within 1 hour post-ROSC and maintain for 72 hours.&#xD;
&#xD;
             -  36-TH (core BT 36℃) or 33-TH (core BT 33℃) for 24 hours&#xD;
&#xD;
             -  Rewarming 0.25℃/h in 33-TH group&#xD;
&#xD;
             -  Core temperature &lt; 37.5℃ for 72 hours&#xD;
&#xD;
           All patients will be treated per the postresuscitation care protocol. Target treatment&#xD;
           will include&#xD;
&#xD;
             -  Target: central venous pressure (CVP) (8 - 12 mmHg), mean arterial pressure (MAP)&#xD;
                (&gt; 65 mmHg), central venous oxygen saturation (ScvO2) (&gt; 70%)&#xD;
&#xD;
             -  Seizure control, shivering control as appropriate&#xD;
&#xD;
             -  Coronary intervention as soon as possible if needed&#xD;
&#xD;
             -  Infection control if indicated&#xD;
&#xD;
             -  Other supportive care&#xD;
&#xD;
           Monitoring data including&#xD;
&#xD;
             -  CVP, MAP, ScvO2, lactate, neuron specific enolase (NSE), end-tidal carbon dioxide&#xD;
                (EtCO2), input-output (I/O) balance&#xD;
&#xD;
             -  Intermittent electroencephalography (EEG) monitoring (2 times/72 hours)&#xD;
&#xD;
             -  Laboratory data including arterial blood gas analysis (ABGA), complete blood count&#xD;
                (CBC), liver function test (LFT), electrolyte, blood urea nitrogen/creatinine&#xD;
                (BUN/Cr), et al.&#xD;
&#xD;
             -  SctO2&#xD;
&#xD;
             -  Core (esophageal or bladder) temperature&#xD;
&#xD;
        4. Data Collection&#xD;
&#xD;
      Study data will be collected in the following manner:&#xD;
&#xD;
      • All data will be collected on appropriate Case Report Forms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Actual">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>From the results of previous studies, we assumed that the mean difference in rSO2 at 72 h between the 36℃ or 33℃ groups would be 3% with 4% of standard deviation. By a referral (2015-0207) to the Medical Research Collaborating Center (MRCC) of SNUH/SNUMC, a sample size of at least 58 (29 per group) was calculated with a power of 0.8 and a significance level of 0.05. Considering an unexpected loss of 15%, the study was planned for 66 participants.&#xD;
Randomization was performed by the 4, 6-block randomization method at the MRCC SNUH/SNUMC web-site (http://mrcc.snu.ac.kr).</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Primary and secondary outcomes were assessed by an investigator blinded to this study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The comparison of the 72-hour SctO2 level between the 36-TH and 33-TH groups in cardiac arrest victims</measure>
    <time_frame>72 hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The comparison of the 72-hour changes in SctO2 level between the 36-TH and 33-TH groups</measure>
    <time_frame>0, 24, and 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The comparison of the severity scores between the 36-TH and 33-TH groups</measure>
    <time_frame>0, 24, and 72 hours</time_frame>
    <description>APACHE II score&#xD;
Sequential Organ Failure Assessment (SOFA) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The comparison of the serum biomarker levels between the 36-TH and 33-TH groups</measure>
    <time_frame>0, 24, and 72 hours</time_frame>
    <description>Neuron specific enolase&#xD;
Cytokines&#xD;
Antioxidants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The comparison of the number of patients with survival discharge between the 36-TH and 33-TH groups</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The comparison of the 6-month cerebral performance scale (CPC) between the 36-TH and 33-TH groups</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication of therapeutic hypothermia</measure>
    <time_frame>72 hours</time_frame>
    <description>Bleeding requiring transfusion&#xD;
Fatal arrhythmia requiring intervention&#xD;
Electrolyte imbalance: newly developed abnormal values&#xD;
Hyper/hypoglycemia&#xD;
Sepsis/pneumonia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Heart Arrest</condition>
  <arm_group>
    <arm_group_label>36-TH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Core temperature 36℃ of targeted temperature management (36-TH) for 24 hours in cardiac arrest victims using Arctic Sun.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>33-TH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Core temperature 33℃ of targeted temperature management (36-TH) for 24 hours in cardiac arrest victims using Arctic Sun.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Arctic Sun</intervention_name>
    <description>Targeted temperature management for 24 hours with core temperature 36℃ or 33℃</description>
    <arm_group_label>33-TH</arm_group_label>
    <arm_group_label>36-TH</arm_group_label>
    <other_name>External cooling device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Comatose patients successfully resuscitated from cardiac arrest&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 18 years old&#xD;
&#xD;
          -  Definite non-cardiac cause arrest&#xD;
&#xD;
          -  Contraindication to TH Active bleeding, coagulopathy, fatal arrhythmia, severe&#xD;
             infectious condition&#xD;
&#xD;
          -  Presence of advanced directives to withhold or withdraw life-sustaining treatment&#xD;
&#xD;
          -  Expected survival &lt; 72 hours&#xD;
&#xD;
          -  Underlying low CPC (≤ 3)&#xD;
&#xD;
          -  No informed consent&#xD;
&#xD;
          -  Follow-up loss&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gil Joon Suh, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National Univerisity College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002 Feb 21;346(8):549-56. Erratum in: N Engl J Med 2002 May 30;346(22):1756.</citation>
    <PMID>11856793</PMID>
  </reference>
  <reference>
    <citation>Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J, Hovdenes J, Kjaergaard J, Kuiper M, Pellis T, Stammet P, Wanscher M, Wise MP, Åneman A, Al-Subaie N, Boesgaard S, Bro-Jeppesen J, Brunetti I, Bugge JF, Hingston CD, Juffermans NP, Koopmans M, Køber L, Langørgen J, Lilja G, Møller JE, Rundgren M, Rylander C, Smid O, Werer C, Winkel P, Friberg H; TTM Trial Investigators. Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med. 2013 Dec 5;369(23):2197-206. doi: 10.1056/NEJMoa1310519. Epub 2013 Nov 17.</citation>
    <PMID>24237006</PMID>
  </reference>
  <results_reference>
    <citation>Buunk G, van der Hoeven JG, Meinders AE. A comparison of near-infrared spectroscopy and jugular bulb oximetry in comatose patients resuscitated from a cardiac arrest. Anaesthesia. 1998 Jan;53(1):13-9.</citation>
    <PMID>9505736</PMID>
  </results_reference>
  <results_reference>
    <citation>Suffoletto B, Kristan J, Rittenberger JC, Guyette F, Hostler D, Callaway C. Near-infrared spectroscopy in post-cardiac arrest patients undergoing therapeutic hypothermia. Resuscitation. 2012 Aug;83(8):986-90. doi: 10.1016/j.resuscitation.2012.03.021. Epub 2012 Apr 19.</citation>
    <PMID>22521725</PMID>
  </results_reference>
  <results_reference>
    <citation>Meex I, Dens J, Jans F, Boer W, Vanhengel K, Vundelinckx G, Heylen R, De Deyne C. Cerebral tissue oxygen saturation during therapeutic hypothermia in post-cardiac arrest patients. Resuscitation. 2013 Jun;84(6):788-93. doi: 10.1016/j.resuscitation.2013.01.003. Epub 2013 Jan 8.</citation>
    <PMID>23313422</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Temperature</keyword>
  <keyword>Hypothermia</keyword>
  <keyword>Brain</keyword>
  <keyword>Oxygen</keyword>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

